Literature DB >> 23067362

The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response.

Christopher R Bolen1, Michael D Robek, Leonid Brodsky, Vincent Schulz, Joseph K Lim, Milton W Taylor, Steven H Kleinstein.   

Abstract

Blood transcriptional profiling is a powerful tool for understanding global changes after infection, and may be useful for prognosis and prediction of drug treatment responses. This study characterizes the effects of chronic hepatitis C virus (HCV) infection on gene expression by analyzing blood samples from 10 treatment-naïve HCV patients and 6 healthy volunteers. Differential expression analysis of microarray data from peripheral blood mononuclear cells (PBMCs) identified a 136-gene signature, including 66 genes elevated in infected individuals. Most of the upregulated genes were associated with interferon (IFN) activity (including members of the OAS and MX families, ISG15, and IRF7), suggesting an ongoing immune response. This HCV signature was also found to be consistently enriched in many other viral infection and vaccination datasets. These genes were validated using a second cohort composed of 5 HCV patients and 5 healthy volunteers, confirming the upregulation of the IFN signature. In summary, this is the first study to directly compare blood transcriptional profiles from HCV patients with healthy controls. The results show that chronic HCV infection has a pronounced effect on gene expression in PBMCs of infected individuals, and significantly elevates the expression of a subset of IFN-stimulated genes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23067362      PMCID: PMC3539252          DOI: 10.1089/jir.2012.0037

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  42 in total

1.  HCV-RNA positivity in peripheral blood mononuclear cells of patients with chronic HCV infection: does it really mean viral replication?

Authors:  V Meier; S Mihm; P Braun Wietzke; G Ramadori
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Serum intercellular adhesion molecule 1 variations in young children with acute otitis media.

Authors:  Keyi Liu; Janet Casey; Michael Pichichero
Journal:  Clin Vaccine Immunol       Date:  2010-10-06

Review 3.  Failure of innate and adaptive immune responses in controlling hepatitis C virus infection.

Authors:  Robert Thimme; Marco Binder; Ralf Bartenschlager
Journal:  FEMS Microbiol Rev       Date:  2012-01-04       Impact factor: 16.408

Review 4.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report.

Authors:  Ming T Tsuang; Nadine Nossova; Tom Yager; Min-Min Tsuang; Shi-Chin Guo; Kou Ge Shyu; Stephen J Glatt; C C Liew
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-02-05       Impact factor: 3.568

Review 7.  Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses.

Authors:  Barbara Rehermann
Journal:  Semin Liver Dis       Date:  2007-05       Impact factor: 6.115

8.  Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers.

Authors:  Maria W Smith; Zhaoxia N Yue; Marcus J Korth; Hao A Do; Loreto Boix; Nelson Fausto; Jordi Bruix; Robert L Carithers; Michael G Katze
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425

9.  Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma.

Authors:  Natalie C Twine; Jennifer A Stover; Bonnie Marshall; Gary Dukart; Manuel Hidalgo; Walter Stadler; Theodore Logan; Janice Dutcher; Gary Hudes; Andrew J Dorner; Donna K Slonim; William L Trepicchio; Michael E Burczynski
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

10.  Gene expression profiling during early acute febrile stage of dengue infection can predict the disease outcome.

Authors:  Eduardo J M Nascimento; Ulisses Braga-Neto; Carlos E Calzavara-Silva; Ana L V Gomes; Frederico G C Abath; Carlos A A Brito; Marli T Cordeiro; Ana M Silva; Cecilia Magalhães; Raoni Andrade; Laura H V G Gil; Ernesto T A Marques
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

View more
  22 in total

1.  HIV-1 Tat Protein Activates both the MyD88 and TRIF Pathways To Induce Tumor Necrosis Factor Alpha and Interleukin-10 in Human Monocytes.

Authors:  Rémi Planès; Nawal Ben Haij; Kaoutar Leghmari; Manutea Serrero; Lbachir BenMohamed; Elmostafa Bahraoui
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

2.  Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection.

Authors:  Cherie T Ng; Brian M Sullivan; John R Teijaro; Andrew M Lee; Megan Welch; Stephanie Rice; Kathleen C F Sheehan; Robert D Schreiber; Michael B A Oldstone
Journal:  Cell Host Microbe       Date:  2015-05-13       Impact factor: 21.023

3.  Type I interferon suppresses virus-specific B cell responses by modulating CD8+ T cell differentiation.

Authors:  E Ashley Moseman; Tuoqi Wu; Juan Carlos de la Torre; Pamela L Schwartzberg; Dorian B McGavern
Journal:  Sci Immunol       Date:  2016-10-21

4.  Impaired toll-like receptor 3-mediated immune responses from macrophages of patients chronically infected with hepatitis C virus.

Authors:  Feng Qian; Christopher R Bolen; Chunxia Jing; Xiaomei Wang; Wei Zheng; Hongyu Zhao; Erol Fikrig; R Douglas Bruce; Steven H Kleinstein; Ruth R Montgomery
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

5.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

6.  Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.

Authors:  Jun Hou; Gertine van Oord; Zwier M A Groothuismink; Mark A A Claassen; Kim Kreefft; Fatiha Zaaraoui-Boutahar; Wilfred F J van IJcken; Albert D M E Osterhaus; Harry L A Janssen; Arno C Andeweg; Robert J de Knegt; Andre Boonstra
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

Review 7.  Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes.

Authors:  Cherie T Ng; Juan L Mendoza; K Christopher Garcia; Michael B A Oldstone
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

8.  Interferon-driven deletion of antiviral B cells at the onset of chronic infection.

Authors:  Benedict Fallet; Kerstin Narr; Yusuf I Ertuna; Melissa Remy; Rami Sommerstein; Karen Cornille; Mario Kreutzfeldt; Nicolas Page; Gert Zimmer; Florian Geier; Tobias Straub; Hanspeter Pircher; Kevin Larimore; Philip D Greenberg; Doron Merkler; Daniel D Pinschewer
Journal:  Sci Immunol       Date:  2016-10-21

9.  Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon.

Authors:  Hisashi Akiyama; Nora-Guadalupe Pina Ramirez; Gregory Gibson; Christopher Kline; Simon Watkins; Zandrea Ambrose; Suryaram Gummuluru
Journal:  J Virol       Date:  2017-10-13       Impact factor: 6.549

10.  USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study.

Authors:  Sona Frankova; Milan Jirsa; Dusan Merta; Magdalena Neroldova; Petr Urbanek; Renata Senkerikova; Julius Spicak; Jan Sperl
Journal:  Ther Clin Risk Manag       Date:  2015-12-17       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.